← All companies
RECURSION PHARMACEUTICALS, INC.
RXRX - CIK 0001601830
Market cap$1.61 B
Rank#2258
SEC filings908
RECURSION PHARMACEUTICALS, INC. trades as RXRX and has a market capitalization of $1.61 B, making it the #2258 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $74.68M, up 26.9% from the prior year and net income of -$644.76M. This page tracks RECURSION PHARMACEUTICALS, INC. through 908 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$74.68MFY 2025
Net income (latest FY)-$644.76MFY 2025
Operating cash flow (latest FY)-$371.81MFY 2025
Total assets (latest FY)$1.47BFY 2025
Net margin-863.4%latest FY
Financial performance
Over the last 6 fiscal years RECURSION PHARMACEUTICALS, INC.'s revenue grew from $2.32M to $74.68M, a compound annual growth rate of 78.4%. Net profit margin expanded from -2668.3% to -863.4% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $1.61 B
- Share price (derived)market cap / shares outstanding
- $3.04
- EPS (diluted)FY 2025
- $-1.44
- Shares outstandingas of 2026-03-31
- 0.53B
- Total equityas of 2026-03-31
- $1.02B
- Return on equity
- -62.9%
- Cash & equivalentsas of 2026-03-31
- $654.47M
- Current ratioas of 2026-03-31
- 5.47
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider trade | 4 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-07 |
Recent press releases
- Recursion to Report First Quarter 2026 Business Updates and ...2026-04-29
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 | Recursion Pharmaceuticals, Inc.
- Recursion Reports Third Quarter 2025 Financial Results and ...2025-11-05
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Recursion Pharmaceuticals, Inc.
- Recursion Reports Second Quarter 2025 Financial Results and ...2025-08-05
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | Recursion Pharmaceuticals, Inc.
Similar companies
The largest companies sharing RECURSION PHARMACEUTICALS, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is RECURSION PHARMACEUTICALS, INC.'s market cap?
RECURSION PHARMACEUTICALS, INC. (RXRX) has a market capitalization of $1.61 B as of 2026-06-11, ranking #2258 among US-listed companies.
How much revenue does RECURSION PHARMACEUTICALS, INC. make?
RECURSION PHARMACEUTICALS, INC. reported revenue of $74.68M for fiscal year 2025, an increase of 26.9% year over year.
Is RECURSION PHARMACEUTICALS, INC. profitable?
In its latest fiscal year RECURSION PHARMACEUTICALS, INC. reported a net loss of $644.76M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.